Cingulate (CING) Stock Overview
A biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
CING Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Cingulate Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.22 |
| 52 Week High | US$20.83 |
| 52 Week Low | US$1.80 |
| Beta | -0.80 |
| 1 Month Change | 28.89% |
| 3 Month Change | 24.88% |
| 1 Year Change | 22.54% |
| 3 Year Change | -98.27% |
| 5 Year Change | n/a |
| Change since IPO | -99.51% |
Recent News & Updates
Shareholder Returns
| CING | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -7.8% | 3.6% | 1.5% |
| 1Y | 22.5% | -6.8% | 17.7% |
Return vs Industry: CING exceeded the US Pharmaceuticals industry which returned -5.9% over the past year.
Return vs Market: CING exceeded the US Market which returned 17.3% over the past year.
Price Volatility
| CING volatility | |
|---|---|
| CING Average Weekly Movement | 9.8% |
| Pharmaceuticals Industry Average Movement | 10.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CING has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CING's weekly volatility has decreased from 46% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 13 | Shane Schaffer | www.cingulate.com |
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical efficacy and safety trials for the treatment of ADHD in children, adolescents, and adults; and CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and related disorders.
Cingulate Inc. Fundamentals Summary
| CING fundamental statistics | |
|---|---|
| Market cap | US$23.35m |
| Earnings (TTM) | -US$16.38m |
| Revenue (TTM) | n/a |
Is CING overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CING income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$9.86m |
| Gross Profit | -US$9.86m |
| Other Expenses | US$6.52m |
| Earnings | -US$16.38m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.86 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 85.1% |
How did CING perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/28 16:24 |
| End of Day Share Price | 2025/07/28 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cingulate Inc. is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Nazibur Rahman | Maxim Group |